Markt geschlossen· · CAD · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
SASKATOON, Saskatchewan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (TSXV: PCRX) (“PharmaCorp” or the “Corporation”) today announced changes to its Board of Directors, Board committee leadership and Corporate Secretary as the Corporation prepares for its 2026 Annual General and Special Meeting of Security Holders (the “2026 AGSM”). Effective August 31, 2026, Calvin Leroux will step down as a director of PharmaCorp and as Chair of the Corporation’s Corporate Governance and Compensation
Second quarter 2026 revenue up 75.8% compared to the second quarter of 2025Second quarter 2026 gross profit increased 78.2% compared to the second quarter of 2025Second quarter same-store sales were up 3.8%, and same-store prescription sales were up 5.2%, both compared to the second quarter of 2025 SASKATOON, Saskatchewan, Aug. 20, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy services and consolidation platform, today reported i
Purchase price of approximately $2.47 millionAcquisition increases PharmaCorp's operating network to 16 pharmaciesNew definitive share purchase agreement executed for a PharmaChoice Canada-bannered pharmacy in Western Canada at a purchase price of approximately $1.3 millionNew definitive asset purchase agreement executed for the prescription files of an I.D.A.-bannered pharmacy in Western CanadaSaskatoon, Saskatchewan--(Newsfile Corp. - August 18, 2026) - PHARMACORP RX INC. (TSXV:...
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.